ADAP Insider Trading Activity and SEC Form 4 Filings
ADAP insider trading summary
No open-market insider purchases or sales of Adaptimmune Therapeutics PLC (ADAP) have been reported on SEC Form 4 in the past 12 months.
Latest ADAP insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 2, 2025 | Gavin Wood | Chief Financial Officer | Sell | $950 (96,000 @ $0.01) |
| Aug 28, 2025 | William C Bertrand JR | Chief Operating Officer | Sell | $2K (207,000 @ $0.01) |
| Aug 18, 2025 | Ali Behbahani | Insider | Sell | $176K (14,671,794 @ $0.01) |
| Aug 15, 2025 | Ali Behbahani | Insider | Sell | $53K (4,828,206 @ $0.01) |
| Jul 30, 2025 | EcoR1 Capital, LLC | 10% Owner | Sell | $2.8M (27,433,338 @ $0.10) |
| Jul 29, 2025 | EcoR1 Capital, LLC | 10% Owner | Sell | $272K (2,687,460 @ $0.10) |
| Jul 28, 2025 | EcoR1 Capital, LLC | 10% Owner | Sell | $3.8M (33,931,740 @ $0.11) |
| Jan 17, 2025 | Elliot Norry | Chief Medical Officer | Sell | $3K (5,584 @ $0.58) |
| Jan 17, 2025 | William C Bertrand JR | Chief Operating Officer | Sell | $3K (5,584 @ $0.58) |
| Jan 17, 2025 | Adrian Rawcliffe | Chief Executive Officer | Sell | $18K (30,601 @ $0.58) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.